Peck Stephanie Knatz, Brewerton Timothy D, Fisher Hannah, Trim Julie, Shao Samantha, Modlin Nadav Liam, Kim Jessie, Finn Daphna M, Kaye Walter H
Department of Psychiatry, University of California, San Diego, CA, USA.
Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA.
J Eat Disord. 2025 May 26;13(1):89. doi: 10.1186/s40337-025-01274-2.
Psychedelic treatment is a rapidly emerging therapeutic approach for a host of chronic, difficult to treat psychiatric disorders, including anorexia nervosa (AN). Trauma and its sequelae, such as dissociation, often contribute to comorbidity and treatment refractoriness.
In this report, we describe the therapeutic emergence of previously dissociated traumatic memories of sexual assault in 2 of 10 research participants with AN while receiving psilocybin treatment.
Ten female adults who met DSM-5 criteria for AN or pAN (partial remission) participated in an open pilot study evaluating the safety, tolerability and preliminary efficacy of psilocybin-assisted psychotherapy. Participants received a 25-mg dose of investigational drug COMP360, a proprietary pharmaceutical-grade synthetic psilocybin formulation developed by COMPASS Pathfinder Ltd. administered in conjunction with psychological support. Participants also received two integration therapy sessions on days 1 and 7 after dosing, and they were reassessed at 1 and 3 months. Participants were interviewed using a semi-structured interview to understand qualitative perspectives of treatment and its effect on AN.
RESULTS/OUTCOMES: Both patients described in this report significantly benefited from the emergence and processing of previously dissociated information (dissociative amnesia), and both patients subsequently attained remission of their AN psychopathology at 3-month follow-up as determined by global scores on the Eating Disorder Examination Questionnaire (EDE-Q) and clinically meaningful weight gain.
CONCLUSIONS/INTERPRETATION: PT may hold promise not only in the treatment of eating disorders but also trauma-related disorders, including PTSD and dissociative amnesia. Potential mechanisms of psilocybin's facilitation of remembering and processing traumatic material is reviewed.
迷幻疗法是一种迅速兴起的治疗方法,用于治疗一系列慢性、难治性精神疾病,包括神经性厌食症(AN)。创伤及其后遗症,如解离,往往导致共病和治疗难治性。
在本报告中,我们描述了10名患有AN的研究参与者中有2人在接受裸盖菇素治疗时,先前解离的性侵犯创伤记忆的治疗性浮现。
10名符合AN或pAN(部分缓解)的DSM-5标准的成年女性参与了一项开放的试点研究,评估裸盖菇素辅助心理治疗的安全性、耐受性和初步疗效。参与者接受了25毫克剂量的研究药物COMP360,这是一种由COMPASS Pathfinder Ltd.开发的专利医药级合成裸盖菇素制剂,并结合心理支持进行给药。参与者在给药后的第1天和第7天还接受了两次整合治疗,并在1个月和3个月时进行了重新评估。使用半结构化访谈对参与者进行访谈,以了解治疗的定性观点及其对AN的影响。
结果/结果:本报告中描述的两名患者均从先前解离信息(解离性遗忘)的浮现和处理中显著受益,并且两名患者在3个月的随访中均实现了AN精神病理学的缓解,这由饮食失调检查问卷(EDE-Q)的总体评分和临床上有意义的体重增加所确定。
结论/解释:迷幻疗法不仅在治疗饮食失调方面可能有前景,而且在治疗与创伤相关的疾病方面,包括创伤后应激障碍和解离性遗忘方面也可能有前景。本文综述了裸盖菇素促进记忆和处理创伤性材料的潜在机制。